stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.46
0.56
+4.03%
Follow BHVN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 940.46% | (799.46%) | (333.00%) | (310.75%) |
+8 more TTM periods Free account |
|
| (161.32%) | (127.41%) | (139.99%) | (138.54%) | ||
ROIC |
(6,659.91%) | (9,245.36%) | (1,733.01%) | 0.00% | |
Return on Tangible Assets |
(378.31%) | (235.69%) | (185.67%) | (275.31%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.13) | (3.40) | (4.03) | (5.67) | |
Free Cash Flow |
(473.18) | (512.10) | (594.23) | (610.15) | |
Capital Expenditures |
(0.65) | (0.71) | — | (0.71) | |
| Other line items | |||||
Cash ROIC |
(144.63%) | (94.91%) | (82.62%) | (100.01%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.87 | 0.87 | 0.92 | 0.82 | |
Depreciation/Fixed assets |
0.64 | 0.68 | 0.66 | 0.62 | |
Capex/Depreciation |
(0.07) | (0.07) | 0.00 | (0.07) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.13) | (3.39) | (4.03) | (5.66) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026